Clinical Trial Update: Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating donor peripheral stem cell transplant and donor natural killer cell transplant after conditioning with total-body irradiation, thiotepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Fludarabine (Fludarabine)
• Muromonab-CD3 (muromonab-CD3)
• THIOTEPA (THIOTEPA)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Graft Versus Host Disease, Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2017-05-24